TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17907490

Group type: EXPERIMENTAL
Intervention: Very high intensity LED unit (Mini LED) in fast mode (10 seconds @ 1,100 mW/cm2)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Very high intensity LED unit (Mini LED) in soft-start mode (pulse mode: ten 1-second flashes @ 1,100 mW/cm2)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Conventional LED unit (Elipar Freelight) in standard mode (40 seconds @ 400 mW/cm2)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Conventional LED unit (Elipar Freelight) in exponential mode (exponential increase from 0 to 400 mW/cm2 within 12 seconds followed by 28 seconds @ 400 mW/cm2)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional halogen unit (Optilux) in standard mode (Control group) (40 seconds @ 600 mW/cm2)
Number of subjects: 120
Study: 16236040

Group type: EXPERIMENTAL
Intervention: Ketoconazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 0
Study: 11726592

Group type: EXPERIMENTAL
Intervention: Hydrosalpinx patients
Number of subjects: 5

Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Mathematical simulations
Number of subjects: 5
Study: 9142512

Group type: EXPERIMENTAL
Intervention: Elderly healthy subjects (75-104 years)
Number of subjects: 576
Study: 7870676

Group type: EXPERIMENTAL
Intervention: Liposomal tetracaine (1F2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glaxal base tetracaine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Liposomal tetracaine (23C2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: PEG Ointment tetracaine
Number of subjects: 0
Study: 3067252

Group type: EXPERIMENTAL
Intervention: Combined estrogen‐androgen preparation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estrogen alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Androgen alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hysterectomy with retained ovaries
Number of subjects: 0
Study: 2351625

Group type: EXPERIMENTAL
Intervention: 750 mg intravenous dose of cefuroxime
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 500 mg oral dose of cefuroxime axetil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AUC0-6 h after oral dosage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Abbreviated methods of assessing bioavailability
Number of subjects: 0
Study: 20343

Group type: EXPERIMENTAL
Intervention: Vacuum Aspiration (VA)
Number of subjects: 420

Group type: COMPARATOR
Intervention: D & C
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Both D & C and Vacuum Aspiration
Number of subjects: 420
Study: 31809308

Group type: EXPERIMENTAL
Intervention: Dapivirine vaginal ring
Number of subjects: 100

Group type: COMPARATOR
Intervention: Receptive anal intercourse (RAI)
Number of subjects: 100
Study: 30790345

Group type: EXPERIMENTAL
Intervention: GSK3008356 (DGAT1 inhibitor)
Number of subjects: 104
Study: 27307397

Group type: EXPERIMENTAL
Intervention: MVI (misoprostol vaginal insert)
Number of subjects: 1358

Group type: COMPARATOR
Intervention: DVI (dinoprostone vaginal insert)
Number of subjects: 1358
Study: 24911427

Group type: EXPERIMENTAL
Intervention: Rapid-weight-reduction (RWR) group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gradual-weight-reduction (GWR) group
Number of subjects: 0
Study: 23268593

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 300 mg plus 100 mg dimethicone and water up to 100 ml
Number of subjects: 177

Group type: COMPARATOR
Intervention: Dimethicone 100 mg (5 ml at 20 mg/ml) plus water up to 100 ml
Number of subjects: 177
Study: 21972619

Group type: EXPERIMENTAL
Intervention: Acupuncture therapy combined with SSRI (observation group 1)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Electroacupuncture therapy combined with SSRI (observation group 2)
Number of subjects: 75

Group type: COMPARATOR
Intervention: SSRI (control group)
Number of subjects: 75
Study: 19858123

Group type: EXPERIMENTAL
Intervention: Three reminder letters mailed to GPs after dissemination of a Dementia Guideline
Number of subjects: 320

Group type: COMPARATOR
Intervention: Control group (no reminder letters)
Number of subjects: 320
Study: 16507185

Group type: EXPERIMENTAL
Intervention: Hyperbaric lidocaine 20 mg and ropivacaine 5 mg (Group LR)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Hyperbaric ropivacaine 10 mg (Group R)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Group LR
Number of subjects: 56

Group type: COMPARATOR
Intervention: Group R
Number of subjects: 56
Study: 15573335

Group type: EXPERIMENTAL
Intervention: Soapsuds enema
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Tap water enema
Number of subjects: 24

Group type: COMPARATOR
Intervention: Polyethylene glycol-electrolyte solution (PEG-ES)
Number of subjects: 24
Study: 11354556

Group type: EXPERIMENTAL
Intervention: Sulfur baths (balneotherapy) for 10 days at the Dead Sea spa
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 48
Study: 9216606

Group type: EXPERIMENTAL
Intervention: Anaesthetic booklet group
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 140
Study: 8128430

Group type: EXPERIMENTAL
Intervention: Prednisone (P), 1 mg/kg for 3 weeks, followed by either continued P for an additional 6 weeks, tapering P and beginning cyclophosphamide (C), 2 mg/kg, or continuing P and adding C.
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (C), 2 mg/kg.
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Combination of Prednisone (P) and Cyclophosphamide (C).
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Prednisone (P) and Cyclophosphamide (C).
Number of subjects: 31
Study: 2887191

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 29641596

Group type: EXPERIMENTAL
Intervention: Modifying the amount consumed of foods (type-1)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Replacing food items by items from the same group or eaten at the same time (type-3)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Replacing food items within the same subgroup (type-2)
Number of subjects: 115
Study: 27552517

Group type: EXPERIMENTAL
Intervention: AR-12286 0.5% or 0.7% topical solution, administered once daily for 24 weeks.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: AR-12286 discontinued after week 24.
Number of subjects: 10
Study: 26633931

Group type: EXPERIMENTAL
Intervention: Epsilon aminocaproic acid (n=26)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (n=26)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (0.9% normal saline, n=26)
Number of subjects: 78
Study: 24324743

Group type: EXPERIMENTAL
Intervention: Declarative word‐pair task
Number of subjects: 24

Group type: COMPARATOR
Intervention: Non‐learning control task
Number of subjects: 24
Study: 20514817

Group type: EXPERIMENTAL
Intervention: Law and justice curricula
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Interaction curricula
Number of subjects: 123

Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Intervention (both curricula)
Number of subjects: 123
Study: 18925316

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/day for 4 weeks
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 16931936

Group type: EXPERIMENTAL
Intervention: TMC278 (25, 50, 100, or 150 mg once-daily for 7 days)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: TMC278
Number of subjects: 47
Study: 12745697

Group type: EXPERIMENTAL
Intervention: Participative standard with performance feedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Assigned standard with performance feedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monetary incentive with assigned or participative standard with feedback
Number of subjects: 0
Study: 11768837

Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg every 6 hours for a total of 7 doses
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg every 6 hours for a total of 7 doses
Number of subjects: 14
Study: 9832953

Group type: COMPARATOR
Intervention: Intranasal heroin (placebo, 12.5, 25, 50, 100 mg)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Intranasal heroin (100 mg)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Intranasal heroin (various doses)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Intranasal heroin
Number of subjects: 5
Study: 7971646

Group type: EXPERIMENTAL
Intervention: Immunosuppressive treatment (prednisone and azathioprine for 3 months)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 38
Study: 3584203

Group type: EXPERIMENTAL
Intervention: Early mobilisation in a cast which restricted extension
Number of subjects: 187

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 187
Study: 31707770

Group type: EXPERIMENTAL
Intervention: wire-in (IFWE inserted and remained within the muscle during testing)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: wire-out (IFWE inserted and immediately removed)
Number of subjects: 40

Group type: COMPARATOR
Intervention: baseline condition (without IFWE insertion)
Number of subjects: 40
Study: 30455177

Group type: EXPERIMENTAL
Intervention: Default option nudge (high-value options presented as default)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional menu display (no nudges)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Partition display nudge (low-value options presented horizontally, high-value options listed vertically)
Number of subjects: 120
Study: 29121282

Group type: EXPERIMENTAL
Intervention: Normal Saline (NS)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Plasma-Lyte 148® (PL)
Number of subjects: 49
Study: 26123384

Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Plasmalyte
Number of subjects: 50
Study: 23761484

Group type: EXPERIMENTAL
Intervention: ω‐3 PUFA supplementation (400 mg DHA daily)
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: ω‐3 PUFA supplementation
Number of subjects: 261
Study: 22279783

Group type: EXPERIMENTAL
Intervention: Selzink medicine, a one-month course of therapy
Number of subjects: 0
Study: 19193572

Group type: EXPERIMENTAL
Intervention: Pharmacist-delivered face-to-face group program (3 sessions)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Standard care telephone session (5-10 minutes)
Number of subjects: 101
Study: 16796760

Group type: EXPERIMENTAL
Intervention: Additional CD-ROM education (E)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Standard information (S)
Number of subjects: 230
Study: 12771602

Group type: EXPERIMENTAL
Intervention: 4-day group
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: 7-day group
Number of subjects: 258
Study: 11097668

Group type: EXPERIMENTAL
Intervention: 1.2 mL (6 mg) of plain 0.5% bupivacaine (group 1; n = 30)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1.2 mL (6 mg) of hyperbaric 0.5% bupivacaine in 8% glucose (group 2; n = 30)
Number of subjects: 60
Study: 8638546

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy of 5-fluorouracil (5-FU) and high-dose folinic acid (HDFA)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Combination chemotherapy of 5-FU and HDFA plus low-dose alpha-2b interferon
Number of subjects: 100
Study: 1317694

Group type: EXPERIMENTAL
Intervention: Naproxen (loading dose, 400 mg or 500 mg followed by 200 mg or 500 mg three times daily for 5 days)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 6543609

Group type: EXPERIMENTAL
Intervention: Morphine (2.5 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naloxone (10 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 0
Study: 29280866

Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA injected in the lateral eyebrow depressors alone (group 1)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA injected in both the lateral and medial eyebrow depressors (group 2)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Comparison of group 1 and group 2
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Patient satisfaction
Number of subjects: 15
Study: 27460602

Group type: EXPERIMENTAL
Intervention: Weight-loss dietary interventions (four diets varying in macronutrient intakes)
Number of subjects: 811
Study: 24571869

Group type: EXPERIMENTAL
Intervention: Intraoperative blood salvage (IBS) in group I
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 50
Study: 21732418

Group type: EXPERIMENTAL
Intervention: Intervention group (n=79)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (n=81)
Number of subjects: 160
Study: 19950398

Group type: EXPERIMENTAL
Intervention: Fine Needle Aspiration Cytology (FNAC) for benign neoplastic lesions
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Fine Needle Aspiration Cytology (FNAC) for malignant neoplastic lesions
Number of subjects: 100

Group type: COMPARATOR
Intervention: Biopsy (control)
Number of subjects: 100
Study: 17385973

Group type: EXPERIMENTAL
Intervention: FV intervention group
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Motivational interviewing sessions
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Trying more recipes
Number of subjects: 20
Study: 15855257

Group type: EXPERIMENTAL
Intervention: GH (n = 25, approximately 20 microg/kg.d)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: GH (n = 25)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo (n = 15)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control (n = 18)
Number of subjects: 58
Study: 12021220

Group type: EXPERIMENTAL
Intervention: X-sizer thrombectomy system
Number of subjects: 66

Group type: COMPARATOR
Intervention: Conventional PCI alone
Number of subjects: 66
Study: 10464128

Group type: EXPERIMENTAL
Intervention: Azathioprine (40 mg/kg loading dose followed by 2 mg/kg oral for 16 weeks)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Both groups (azathioprine and placebo)
Number of subjects: 96
Study: 9248904

Group type: EXPERIMENTAL
Intervention: Intramuscular sumatriptan 6 mg
Number of subjects: 43

Group type: COMPARATOR
Intervention: Intravenous chlorpromazine, 12.5 mg increments to a maximum of 37.5 mg
Number of subjects: 43
Study: 1911008

Group type: COMPARATOR
Intervention: Continuous i.m. infusion of ketorolac 10 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intermittent i.m. injection of ketorolac 10 mg administered 4-hourly
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7139397

Group type: EXPERIMENTAL
Intervention: 10 mg of succinylcholine (self-taming)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: d-tubocurarine 0.04 mg/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: No pretreatment (control group)
Number of subjects: 60
Study: 30897391

Group type: EXPERIMENTAL
Intervention: Childhood Trauma (CT) - Sexual Abuse
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Childhood Trauma (CT) - Physical Neglect
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Childhood Trauma (CT) - High CT
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Childhood Trauma (CT) - Physical Neglect and Depression
Number of subjects: 82
Study: 28612893

Group type: EXPERIMENTAL
Intervention: Substitute tear + mixture (Bifidobacterium lactis and Bifidobacterium bifido)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Substitute tear (control)
Number of subjects: 40
Study: 26189209

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Venlafaxine-extended release
Number of subjects: 1008

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 1008
Study: 25001440

Group type: EXPERIMENTAL
Intervention: Manuka honey with UMF 19.5
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular tooth brushing regimen
Number of subjects: 0
Study: 22193575

Group type: EXPERIMENTAL
Intervention: Intensive smoking cessation intervention
Number of subjects: 94

Group type: COMPARATOR
Intervention: Minimal smoking cessation intervention
Number of subjects: 94
Study: 20616673

Group type: EXPERIMENTAL
Intervention: 17beta‐E2 (1 mg/d for 1 mo, then 2 mg/d for 2 mo)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 17873238

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 5 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 30 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 16140224

Group type: EXPERIMENTAL
Intervention: cetirizine 10mg daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20

Group type: COMPARATOR
Intervention: screening
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: cetirizine
Number of subjects: 20
Study: 11859907

Group type: EXPERIMENTAL
Intervention: Almotriptan 12.5 mg
Number of subjects: 3500
Study: 10402678

Group type: EXPERIMENTAL
Intervention: Abstract predicates used as prompts
Number of subjects: 5

Group type: COMPARATOR
Intervention: Concrete predicates used as prompts
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Interaction between memory and preferential predicate use
Number of subjects: 5
Study: 7599565

Group type: EXPERIMENTAL
Intervention: CsA-MTX
Number of subjects: 29

Group type: COMPARATOR
Intervention: CsA-MTX-MP
Number of subjects: 29
Study: 2384206

Group type: EXPERIMENTAL
Intervention: Reminder issued to patients in the experimental group during the middle year
Number of subjects: 1175

Group type: COMPARATOR
Intervention: Control group (no reminder issued)
Number of subjects: 1175
Study: 6104498

Group type: EXPERIMENTAL
Intervention: Betaxolol 5 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Betaxolol 10 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Betaxolol 20 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Betaxolol 40 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31426018

Group type: COMPARATOR
Intervention: Deceptive placebo
Number of subjects: 154

Group type: COMPARATOR
Intervention: Open-label placebo
Number of subjects: 154

Group type: COMPARATOR
Intervention: Control
Number of subjects: 154
Study: 28064251

Group type: EXPERIMENTAL
Intervention: Axillary vein access
Number of subjects: 74

Group type: COMPARATOR
Intervention: Cephalic vein access
Number of subjects: 74
Study: 25986292

Group type: EXPERIMENTAL
Intervention: Obesity pamphlet
Number of subjects: 80

Group type: COMPARATOR
Intervention: Stress management pamphlet
Number of subjects: 80
Study: 23434769

Group type: EXPERIMENTAL
Intervention: Telephone follow-ups (4 calls at 7 days, 1 month, 6 months, and 9 months)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Usual clinical practice (control group)
Number of subjects: 300
Study: 20845391

Group type: EXPERIMENTAL
Intervention: 0.5 mg of melatonin every night for 14 days or until discharge
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo every night for 14 days or until discharge
Number of subjects: 145
Study: 19438696

Group type: EXPERIMENTAL
Intervention: Combined protocol
Number of subjects: 100

Group type: COMPARATOR
Intervention: Low-dose dobutamine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Infra-low-dose dipyridamole
Number of subjects: 100
Study: 17657857

Group type: EXPERIMENTAL
Intervention: Autologous blood transfusion (n=30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Allogeneic blood transfusion (n=30)
Number of subjects: 60
Study: 15851822

Group type: EXPERIMENTAL
Intervention: Progressive training over 24 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (CN)
Number of subjects: 16
Study: 11216718

Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty (TKA)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Preoperative demand levels (low vs medium/high)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Demand matching hypothesis
Number of subjects: 279
Study: 9919901

Group type: EXPERIMENTAL
Intervention: FUT-175 (40-160 mg/day) administered during the initial 4 days following surgery
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (non-FUT group) with 455 patients treated without FUT-175
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: OKY-046 as part of standard care
Number of subjects: 34
Study: 8116990

Group type: EXPERIMENTAL
Intervention: Alcoholic patients with cardiomyopathy (Group A)
Number of subjects: 101
Study: 1976298

Group type: EXPERIMENTAL
Intervention: Oral astemizole for 8 weeks
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 26139

Group type: EXPERIMENTAL
Intervention: Celiprolol
Number of subjects: 6

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 6
Study: 31758576

Group type: EXPERIMENTAL
Intervention: PF-06480605 1 mg, 3 mg, 10 mg, 30 mg, 100 mg, 300 mg, 600 mg, or 800 mg IV (SAD)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: PF-06480605 3 × 500 mg IV, or 3 × 30 mg, 3 × 100 mg, or 3 × 300 mg SC every 2 weeks for three doses (MAD)
Number of subjects: 92

Group type: COMPARATOR
Intervention: PF-06480605 (SAD and MAD)
Number of subjects: 92

Group type: COMPARATOR
Intervention: PF-06480605 vs placebo cohorts
Number of subjects: 92
Study: 31156217

Group type: EXPERIMENTAL
Intervention: Ampasse (5, 10, or 25 mg intravenously once a day for 15 days)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sodium chloride 0.9% (placebo)
Number of subjects: 80
Study: 28076709

Group type: EXPERIMENTAL
Intervention: 177Lu-Dotatate (7.4 GBq every 8 weeks, plus best supportive care including octreotide LAR 30 mg IM)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Octreotide LAR (60 mg IM every 4 weeks)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: 177Lu-Dotatate
Number of subjects: 229

Group type: COMPARATOR
Intervention: Octreotide LAR
Number of subjects: 229
Study: 25891440

Group type: EXPERIMENTAL
Intervention: Vilazodone 40 mg/day
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Vilazodone 20 mg/day
Number of subjects: 680

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 680